About the Author
Michael Parnham studied pharmacology at London University, UK and obtained his PhD in pharmacology at Bristol University, subsequently performing postdoctoral work in inflammation at Erasmus University Rotterdam, The Netherlands. He is currently Head of Preclinical Research in the Fraunhofer Institute of Molecular Biology & Applied Ecology, Project Group for Translational Medicine & Pharmacology TMP, Frankfurt am Main, Germany and since 1998 has been Adjunct Professor of Pharmacology & Toxicology at Goethe University Frankfurt. He is also a Fellow of the British Pharmacological Society. Prior to his present position, Dr Parnham was Visiting Scientist in the Hospital for Infectious Diseases Zagreb, Croatia and Director of Preclinical Discovery, GlaxoSmithKline, Zagreb. From 1998 to 2006 he was Head of Pharmacology & Toxicology and then Senior Scientific Advisor at PLIVA, Zagreb and was previously employed for a decade by A. Nattermann and subsequently Rhône-Poulenc Santé in Cologne, Germany, where he rose to become Head of General Biology. Dr Parnham has researched and published extensively on inflammatory mediators and mechanisms, anti-inflammatory, antibiotic and immunomodulatory drugs, toxicology and the pharmacology of selenium. He was Managing Editor of the international journal Inflammation Research from 1992 to 2013 and is editor of several book series, including Milestones in Drug Therapy and Progress in Inflammation Research, and the textbook Principles of Immunopharmacology. He has helped discover and develop 6 compounds up to clinical trials, including 2 novel biologicals and a seleno-organic compound, for which he and his group received the Prix Galien Germany in 1990. Dr Parnham has run a pharmaco-toxicological consultancy in Germany for 8 years, has been involved in discussions with EMEA on drug safety and was a representative of the European Generics Association on the working group for biosimilar drugs. In 2015, he received the Lifetime Achievement Award of the International Association of Inflammation Societies.
